Update in thrombosis: Answers to perplexing questions

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 10, 2005, Pages 907-915

  Federman, Daniel G ^a,b   Brescia, Gina R ^a,b   Moriarty, John P ^a,b   Haskell, Sally G ^a,b   Krishnamurthy, Raj ^a,b   Kirsner, Robert S ^c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PROTHROMBIN; PYRIDOXINE; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING DISORDER; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG SAFETY; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LUNG EMBOLISM; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VEIN DISEASE; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

EID: 27744470552     PISSN: 08911150     EISSN: 08911150     Source Type: Journal    
DOI: 10.3949/ccjm.72.10.907     Document Type: Review

References (48)

1. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345:165-169.
2. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336:393-398.
3. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901-907.
4. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348:1425-1434.
5. Kearon C, Ginsberg J, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349:631-639.
6. Linkins L, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. A meta-analysis. Ann Intern Med 2003; 139:93-900.
7. Hirsch J, Lee AY. How we diagnose and treat deep venous thrombosis. Blood 2002; 99:3102-3110.
8. Kearon C. Long-term management of patients with venous thromboembolism. Circulation 2004; 110(suppl 1):I-10-I-18.
9. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362:523-526.
10. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74:606-611.
11. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332:1661-1665.
12. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population based cohort study. Arch Intern Med 2000; 160:761-768.
13. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7.
14. Van Dongen CJJ, Vink R, Hutten B, et al. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event. Arch Intern Med 2003; 163:1286-1293.
15. Tardy B, Tardy-Poncet B, Laporte-Simitsidis S, et al. Evolution of blood coagulation and fibrinolysis parameters after abrupt versus gradual withdrawal of acenocoumarol in patients with venous thromboembolism: a double blind randomized study. Br J Haematol 1997; 96:174-178.
16. Ascani A, Ilorio A, Agnelli G. Withdrawal of warfarin after deep venous thrombosis: effects of a low fixed dose on rebound thrombin generation. Blood Coagul Fibrinolysis 1999; 10:291-295.
17. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. The Cochrane Library 2005; 1.
18. Federman DG, Kirsner RS. An update on hypercoagulable disorders. Arch Intern Med 2001; 161:1051-1056.
19. Thomas RH. Hypercoaguability syndromes. Arch Intern Med 2001; 161:2433-2439.
20. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344:1222-1231.
21. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thromboembolism in apparently healthy men. N Engl J Med 1995; 332:912-917.
22. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G->A 20210 gene variant. Ann Intern Med 1998; 80:49-51.
23. Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92:2800-2802.
24. Simioni P, Prandoni P, Lensing AWA, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 2000; 96:3329-3333.
25. Eichinger S, Pabinger I, Stumpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77:624-628.
26. Eichinger S, Weltermann A, Mannhalter C, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of Factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002; 162:2357-2360.
27. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H and the Durac Trial Study Group. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation Factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81:684-689.
28. DeStefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both Factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801-806.
29. Margaglione M, D'Andrea G, Colaizzo D, et al. Coexistence of Factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999; 82:1583-1587.
30. Libby P. Multiple mechanisms of thrombosis complicating atherosclerotic plaques. Clin Cardiol 2000; 23:(suppl 6):VI-3-VI-7.
31. Sueishi K, Ichikawa K, Kato K, et al. Atherosclerosis: coagulation and fibrinolysis. Semin Thromb Hemost 1998; 24:255-260.
32. Holvoet P, Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol 1997; 8:320-328.
33. Libertiny G, Hands L. Deep venous thrombosis in peripheral vascular disease. Br J Surg 1999; 86:907-910.
34. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348:1435-1441.
35. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277:642-645.
36. Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162:1182-1189.
37. Vaya A, Mira Y, Ferrando F, et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors Br J Haematol 2002; 118:255-259.
38. Thambyrajah J, Townsent JN. Homocysteine and atherothrombosis: mechanisms for injury. Eur Heart J 2002; 21:967-976.
39. Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with impaired endothelial-dependent vasodilation in humans. Circulation 1997; 95:1119-1121.
40. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ 1998; 316:894-898.
41. Woo KS, Chook P, Lolin YI, et al. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. J Am Coll Cardiol 1999; 34:2022-2026.
42. Tiltle LM, Cummings PM, Giddens K, et al. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000; 36:758-765.
43. Hackman DG, Peterson JC, Pence JD. What level of plasma homocysteine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocysteine levels above and below 14 μmol/L. Am J Hypertens 2000; 12:105-110.
44. Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effects of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of sub clinical atherosclerosis: a randomized, placebo-controlled trial. Lancet 2000; 355:517-522.
45. 6 on clinical outcomes after percutaneous coronary intervention. JAMA 2002; 288:973-979.
46. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345:1593-1600.
47. Lange H, Suryapranta H, De Luca G, et al. Folate therapy and instent restenosis after coronary stenting. N Engl J Med 2004; 350:2673-2681.
48. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004; 291:565-575.